APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Tumor Targeting Peptides

Compare research editions
View pricing & licenses

Selected research

Industry Research

Tumor Targeting Peptides Industry Research Report 2026

Report ID 174043800528 December 2025120 pages

Choose your research edition.

Industry ResearchTumor Targeting Peptides Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Tumor Targeting Peptides Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Tumor Targeting Peptides Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tumor Targeting Peptides Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Tumor Targeting Peptides Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Tumor Targeting Peptides market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Tumor Targeting Peptides is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Tumor Targeting Peptides is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Tumor Targeting Peptides is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Tumor Targeting Peptides include Advanced ChemTech, ASIA BIOSCIENCE CO, Bachem, Biorbyt, Cell Guidance Systems, CPC Scientific Inc, Danaher(Abcam), Merck KGaA and PEPTIDE INSTITUTE, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Tumor Targeting Peptides market in terms of revenue (US$ million) and, where applicable, sales volume (Kg), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Kg) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Tumor Targeting Peptides Market by Company

Advanced ChemTech

ASIA BIOSCIENCE CO

Bachem

Biorbyt

Cell Guidance Systems

CPC Scientific Inc

Danaher(Abcam)

Merck KGaA

PEPTIDE INSTITUTE

RayBiotech

Selleck Chemicals

TargetMol Chemicals

Cayman Chemical

QYAOBIO

Tumor Targeting Peptides Segment by Type

Therapeutic Targeting Peptides

Imaging Targeting Peptides

Tumor Targeting Peptides Segment by Application

Scientific Research

Pharmaceuticals

Tumor Targeting Peptides Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Targeting Peptides market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tumor Targeting Peptides and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Targeting Peptides.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Tumor Targeting Peptides manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Tumor Targeting Peptides by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Tumor Targeting Peptides in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Tumor Targeting Peptides Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Tumor Targeting Peptides Sales (Kg) of Manufacturers (2021-2026) Table 7. Global Tumor Targeting Peptides Sales Market Share by Manufacturers (2021-2026) Table 8. Global Tumor Targeting Peptides Revenue of Manufacturers (2021-2026) Table 9. Global Tumor Targeting Peptides Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Tumor Targeting Peptides Average Price (US$/g) of Manufacturers (2021-2026) Table 11. Global Tumor Targeting Peptides Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Tumor Targeting Peptides, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Tumor Targeting Peptides, Product Type & Application Table 14. Global Tumor Targeting Peptides Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Tumor Targeting Peptides by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Advanced ChemTech Company Information Table 19. Advanced ChemTech Business Overview Table 20. Advanced ChemTech Tumor Targeting Peptides Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 21. Advanced ChemTech Tumor Targeting Peptides Product Portfolio Table 22. Advanced ChemTech Recent Developments Table 23. ASIA BIOSCIENCE CO Company Information Table 24. ASIA BIOSCIENCE CO Business Overview Table 25. ASIA BIOSCIENCE CO Tumor Targeting Peptides Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 26. ASIA BIOSCIENCE CO Tumor Targeting Peptides Product Portfolio Table 27. ASIA BIOSCIENCE CO Recent Developments Table 28. Bachem Company Information Table 29. Bachem Business Overview Table 30. Bachem Tumor Targeting Peptides Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 31. Bachem Tumor Targeting Peptides Product Portfolio Table 32. Bachem Recent Developments Table 33. Biorbyt Company Information Table 34. Biorbyt Business Overview Table 35. Biorbyt Tumor Targeting Peptides Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 36. Biorbyt Tumor Targeting Peptides Product Portfolio Table 37. Biorbyt Recent Developments Table 38. Cell Guidance Systems Company Information Table 39. Cell Guidance Systems Business Overview Table 40. Cell Guidance Systems Tumor Targeting Peptides Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 41. Cell Guidance Systems Tumor Targeting Peptides Product Portfolio Table 42. Cell Guidance Systems Recent Developments Table 43. CPC Scientific Inc Company Information Table 44. CPC Scientific Inc Business Overview Table 45. CPC Scientific Inc Tumor Targeting Peptides Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 46. CPC Scientific Inc Tumor Targeting Peptides Product Portfolio Table 47. CPC Scientific Inc Recent Developments Table 48. Danaher(Abcam) Company Information Table 49. Danaher(Abcam) Business Overview Table 50. Danaher(Abcam) Tumor Targeting Peptides Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 51. Danaher(Abcam) Tumor Targeting Peptides Product Portfolio Table 52. Danaher(Abcam) Recent Developments Table 53. Merck KGaA Company Information Table 54. Merck KGaA Business Overview Table 55. Merck KGaA Tumor Targeting Peptides Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 56. Merck KGaA Tumor Targeting Peptides Product Portfolio Table 57. Merck KGaA Recent Developments Table 58. PEPTIDE INSTITUTE Company Information Table 59. PEPTIDE INSTITUTE Business Overview Table 60. PEPTIDE INSTITUTE Tumor Targeting Peptides Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 61. PEPTIDE INSTITUTE Tumor Targeting Peptides Product Portfolio Table 62. PEPTIDE INSTITUTE Recent Developments Table 63. RayBiotech Company Information Table 64. RayBiotech Business Overview Table 65. RayBiotech Tumor Targeting Peptides Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 66. RayBiotech Tumor Targeting Peptides Product Portfolio Table 67. RayBiotech Recent Developments Table 68. Selleck Chemicals Company Information Table 69. Selleck Chemicals Business Overview Table 70. Selleck Chemicals Tumor Targeting Peptides Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 71. Selleck Chemicals Tumor Targeting Peptides Product Portfolio Table 72. Selleck Chemicals Recent Developments Table 73. TargetMol Chemicals Company Information Table 74. TargetMol Chemicals Business Overview Table 75. TargetMol Chemicals Tumor Targeting Peptides Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 76. TargetMol Chemicals Tumor Targeting Peptides Product Portfolio Table 77. TargetMol Chemicals Recent Developments Table 78. Cayman Chemical Company Information Table 79. Cayman Chemical Business Overview Table 80. Cayman Chemical Tumor Targeting Peptides Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 81. Cayman Chemical Tumor Targeting Peptides Product Portfolio Table 82. Cayman Chemical Recent Developments Table 83. QYAOBIO Company Information Table 84. QYAOBIO Business Overview Table 85. QYAOBIO Tumor Targeting Peptides Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 86. QYAOBIO Tumor Targeting Peptides Product Portfolio Table 87. QYAOBIO Recent Developments Table 88. Global Tumor Targeting Peptides Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 89. Global Tumor Targeting Peptides Sales by Region (2021-2026) & (Kg) Table 90. Global Tumor Targeting Peptides Sales Market Share by Region (2021-2026) Table 91. Global Tumor Targeting Peptides Sales by Region (2027-2032) & (Kg) Table 92. Global Tumor Targeting Peptides Sales Market Share by Region (2027-2032) Table 93. Global Tumor Targeting Peptides Revenue by Region (2021-2026) & (US$ Million) Table 94. Global Tumor Targeting Peptides Revenue Market Share by Region (2021-2026) Table 95. Global Tumor Targeting Peptides Revenue by Region (2027-2032) & (US$ Million) Table 96. Global Tumor Targeting Peptides Revenue Market Share by Region (2027-2032) Table 97. North America Tumor Targeting Peptides Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. North America Tumor Targeting Peptides Sales by Country (2021-2026) & (Kg) Table 99. North America Tumor Targeting Peptides Sales by Country (2027-2032) & (Kg) Table 100. North America Tumor Targeting Peptides Revenue by Country (2021-2026) & (US$ Million) Table 101. North America Tumor Targeting Peptides Revenue by Country (2027-2032) & (US$ Million) Table 102. Europe Tumor Targeting Peptides Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Europe Tumor Targeting Peptides Sales by Country (2021-2026) & (Kg) Table 104. Europe Tumor Targeting Peptides Sales by Country (2027-2032) & (Kg) Table 105. Europe Tumor Targeting Peptides Revenue by Country (2021-2026) & (US$ Million) Table 106. Europe Tumor Targeting Peptides Revenue by Country (2027-2032) & (US$ Million) Table 107. Asia Pacific Tumor Targeting Peptides Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Asia Pacific Tumor Targeting Peptides Sales by Country (2021-2026) & (Kg) Table 109. Asia Pacific Tumor Targeting Peptides Sales by Country (2027-2032) & (Kg) Table 110. Asia Pacific Tumor Targeting Peptides Revenue by Country (2021-2026) & (US$ Million) Table 111. Asia Pacific Tumor Targeting Peptides Revenue by Country (2027-2032) & (US$ Million) Table 112. South America Tumor Targeting Peptides Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. South America Tumor Targeting Peptides Sales by Country (2021-2026) & (Kg) Table 114. South America Tumor Targeting Peptides Sales by Country (2027-2032) & (Kg) Table 115. South America Tumor Targeting Peptides Revenue by Country (2021-2026) & (US$ Million) Table 116. South America Tumor Targeting Peptides Revenue by Country (2027-2032) & (US$ Million) Table 117. Middle East and Africa Tumor Targeting Peptides Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Middle East and Africa Tumor Targeting Peptides Sales by Country (2021-2026) & (Kg) Table 119. Middle East and Africa Tumor Targeting Peptides Sales by Country (2027-2032) & (Kg) Table 120. Middle East and Africa Tumor Targeting Peptides Revenue by Country (2021-2026) & (US$ Million) Table 121. Middle East and Africa Tumor Targeting Peptides Revenue by Country (2027-2032) & (US$ Million) Table 122. Global Tumor Targeting Peptides Sales by Type (2021-2026) & (Kg) Table 123. Global Tumor Targeting Peptides Sales by Type (2027-2032) & (Kg) Table 124. Global Tumor Targeting Peptides Sales Market Share by Type (2021-2026) Table 125. Global Tumor Targeting Peptides Sales Market Share by Type (2027-2032) Table 126. Global Tumor Targeting Peptides Revenue by Type (2021-2026) & (US$ Million) Table 127. Global Tumor Targeting Peptides Revenue by Type (2027-2032) & (US$ Million) Table 128. Global Tumor Targeting Peptides Revenue Market Share by Type (2021-2026) Table 129. Global Tumor Targeting Peptides Revenue Market Share by Type (2027-2032) Table 130. Global Tumor Targeting Peptides Price by Type (2021-2026) & (US$/g) Table 131. Global Tumor Targeting Peptides Price by Type (2027-2032) & (US$/g) Table 132. Global Tumor Targeting Peptides Sales by Application (2021-2026) & (Kg) Table 133. Global Tumor Targeting Peptides Sales by Application (2027-2032) & (Kg) Table 134. Global Tumor Targeting Peptides Sales Market Share by Application (2021-2026) Table 135. Global Tumor Targeting Peptides Sales Market Share by Application (2027-2032) Table 136. Global Tumor Targeting Peptides Revenue by Application (2021-2026) & (US$ Million) Table 137. Global Tumor Targeting Peptides Revenue by Application (2027-2032) & (US$ Million) Table 138. Global Tumor Targeting Peptides Revenue Market Share by Application (2021-2026) Table 139. Global Tumor Targeting Peptides Revenue Market Share by Application (2027-2032) Table 140. Global Tumor Targeting Peptides Price by Application (2021-2026) & (US$/g) Table 141. Global Tumor Targeting Peptides Price by Application (2027-2032) & (US$/g) Table 142. Key Raw Materials Table 143. Raw Materials Key Suppliers Table 144. Tumor Targeting Peptides Distributors List Table 145. Tumor Targeting Peptides Customers List Table 146. Tumor Targeting Peptides Industry Trends Table 147. Tumor Targeting Peptides Industry Drivers Table 148. Tumor Targeting Peptides Industry Restraints Table 149. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Tumor Targeting Peptides Product Image Figure 5. Global Tumor Targeting Peptides Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Tumor Targeting Peptides Market Size (2021-2032) & (US$ Million) Figure 7. Global Tumor Targeting Peptides Sales (2021-2032) & (Kg) Figure 8. Global Tumor Targeting Peptides Average Price (US$/g) & (2021-2032) Figure 9. Therapeutic Targeting Peptides Product Image Figure 10. Imaging Targeting Peptides Product Image Figure 11. Scientific Research Product Image Figure 12. Pharmaceuticals Product Image Figure 13. Global Tumor Targeting Peptides Revenue Share by Manufacturers in 2025 Figure 14. Global Manufacturers of Tumor Targeting Peptides, Manufacturing Sites & Headquarters Figure 15. Global Top 5 and 10 Tumor Targeting Peptides Players Market Share by Revenue in 2025 Figure 16. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Tumor Targeting Peptides Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 18. Global Tumor Targeting Peptides Sales by Region in 2025 Figure 19. Global Tumor Targeting Peptides Revenue by Region in 2025 Figure 20. North America Tumor Targeting Peptides Market Size by Country in 2025 Figure 21. North America Tumor Targeting Peptides Sales Market Share by Country (2021-2032) Figure 22. North America Tumor Targeting Peptides Revenue Market Share by Country (2021-2032) Figure 23. United States Tumor Targeting Peptides Revenue Growth Rate (2021-2032) & (US$ Million) Figure 24. Canada Tumor Targeting Peptides Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Mexico Tumor Targeting Peptides Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Europe Tumor Targeting Peptides Market Size by Country in 2025 Figure 27. Europe Tumor Targeting Peptides Sales Market Share by Country (2021-2032) Figure 28. Europe Tumor Targeting Peptides Revenue Market Share by Country (2021-2032) Figure 29. Germany Tumor Targeting Peptides Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. France Tumor Targeting Peptides Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. U.K. Tumor Targeting Peptides Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Italy Tumor Targeting Peptides Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Russia Tumor Targeting Peptides Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Spain Tumor Targeting Peptides Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Netherlands Tumor Targeting Peptides Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Switzerland Tumor Targeting Peptides Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Sweden Tumor Targeting Peptides Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Poland Tumor Targeting Peptides Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Asia Pacific Tumor Targeting Peptides Market Size by Country in 2025 Figure 40. Asia Pacific Tumor Targeting Peptides Sales Market Share by Country (2021-2032) Figure 41. Asia Pacific Tumor Targeting Peptides Revenue Market Share by Country (2021-2032) Figure 42. China Tumor Targeting Peptides Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Japan Tumor Targeting Peptides Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. South Korea Tumor Targeting Peptides Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. India Tumor Targeting Peptides Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Australia Tumor Targeting Peptides Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Taiwan Tumor Targeting Peptides Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Southeast Asia Tumor Targeting Peptides Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Tumor Targeting Peptides Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. South America Tumor Targeting Peptides Market Size by Country in 2025 Figure 51. South America Tumor Targeting Peptides Sales Market Share by Country (2021-2032) Figure 52. South America Tumor Targeting Peptides Revenue Market Share by Country (2021-2032) Figure 53. Brazil Tumor Targeting Peptides Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Argentina Tumor Targeting Peptides Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Chile Tumor Targeting Peptides Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Middle East and Africa Tumor Targeting Peptides Market Size by Country in 2025 Figure 57. Middle East and Africa Tumor Targeting Peptides Sales Market Share by Country (2021-2032) Figure 58. Middle East and Africa Tumor Targeting Peptides Revenue Market Share by Country (2021-2032) Figure 59. Egypt Tumor Targeting Peptides Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. South Africa Tumor Targeting Peptides Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Israel Tumor Targeting Peptides Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Türkiye Tumor Targeting Peptides Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. GCC Countries Tumor Targeting Peptides Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Global Tumor Targeting Peptides Sales Market Share by Type (2021-2032) Figure 65. Global Tumor Targeting Peptides Revenue Market Share by Type (2021-2032) Figure 66. Global Tumor Targeting Peptides Price (US$/g) by Type (2021-2032) Figure 67. Global Tumor Targeting Peptides Sales Market Share by Application (2021-2032) Figure 68. Global Tumor Targeting Peptides Revenue Market Share by Application (2021-2032) Figure 69. Global Tumor Targeting Peptides Price (US$/g) by Application (2021-2032) Figure 70. Tumor Targeting Peptides Value Chain Figure 71. Tumor Targeting Peptides Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Tumor Targeting Peptides Industry Opportunities and Challenges

Scope & coverage.

Types
  • Therapeutic Targeting Peptides
  • Imaging Targeting Peptides
Applications
  • Scientific Research
  • Pharmaceuticals
Companies covered
  • Advanced ChemTech
  • ASIA BIOSCIENCE CO
  • Bachem
  • Biorbyt
  • Cell Guidance Systems
  • CPC Scientific Inc
  • Danaher(Abcam)
  • Merck KGaA
  • PEPTIDE INSTITUTE
  • RayBiotech
  • Selleck Chemicals
  • TargetMol Chemicals
  • Cayman Chemical
  • QYAOBIO

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Tumor Targeting Peptides Market Size (2021-2032)
  4. 2.2.2 Global Tumor Targeting Peptides Sales (2021-2032)
  5. 2.2.3 Global Tumor Targeting Peptides Market Average Price (2021-2032)
  6. 2.3 Tumor Targeting Peptides by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Therapeutic Targeting Peptides
  9. 2.3.3 Imaging Targeting Peptides
  10. 2.4 Tumor Targeting Peptides by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Scientific Research
  13. 2.4.3 Pharmaceuticals
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Tumor Targeting Peptides Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Tumor Targeting Peptides Sales (Kg) of Manufacturers (2021-2026)
  3. 3.3 Global Tumor Targeting Peptides Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Tumor Targeting Peptides Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Tumor Targeting Peptides Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Tumor Targeting Peptides, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Tumor Targeting Peptides, Product Type & Application
  8. 3.8 Global Manufacturers of Tumor Targeting Peptides, Established Date
  9. 3.9 Global Tumor Targeting Peptides Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Advanced ChemTech
  2. 4.1.1 Advanced ChemTech Company Information
  3. 4.1.2 Advanced ChemTech Business Overview
  4. 4.1.3 Advanced ChemTech Tumor Targeting Peptides Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Advanced ChemTech Tumor Targeting Peptides Product Portfolio
  6. 4.1.5 Advanced ChemTech Recent Developments
  7. 4.2 ASIA BIOSCIENCE CO
  8. 4.2.1 ASIA BIOSCIENCE CO Company Information
  9. 4.2.2 ASIA BIOSCIENCE CO Business Overview
  10. 4.2.3 ASIA BIOSCIENCE CO Tumor Targeting Peptides Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 ASIA BIOSCIENCE CO Tumor Targeting Peptides Product Portfolio
  12. 4.2.5 ASIA BIOSCIENCE CO Recent Developments
  13. 4.3 Bachem
  14. 4.3.1 Bachem Company Information
  15. 4.3.2 Bachem Business Overview
  16. 4.3.3 Bachem Tumor Targeting Peptides Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Bachem Tumor Targeting Peptides Product Portfolio
  18. 4.3.5 Bachem Recent Developments
  19. 4.4 Biorbyt
  20. 4.4.1 Biorbyt Company Information
  21. 4.4.2 Biorbyt Business Overview
  22. 4.4.3 Biorbyt Tumor Targeting Peptides Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Biorbyt Tumor Targeting Peptides Product Portfolio
  24. 4.4.5 Biorbyt Recent Developments
  25. 4.5 Cell Guidance Systems
  26. 4.5.1 Cell Guidance Systems Company Information
  27. 4.5.2 Cell Guidance Systems Business Overview
  28. 4.5.3 Cell Guidance Systems Tumor Targeting Peptides Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Cell Guidance Systems Tumor Targeting Peptides Product Portfolio
  30. 4.5.5 Cell Guidance Systems Recent Developments
  31. 4.6 CPC Scientific Inc
  32. 4.6.1 CPC Scientific Inc Company Information
  33. 4.6.2 CPC Scientific Inc Business Overview
  34. 4.6.3 CPC Scientific Inc Tumor Targeting Peptides Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 CPC Scientific Inc Tumor Targeting Peptides Product Portfolio
  36. 4.6.5 CPC Scientific Inc Recent Developments
  37. 4.7 Danaher(Abcam)
  38. 4.7.1 Danaher(Abcam) Company Information
  39. 4.7.2 Danaher(Abcam) Business Overview
  40. 4.7.3 Danaher(Abcam) Tumor Targeting Peptides Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Danaher(Abcam) Tumor Targeting Peptides Product Portfolio
  42. 4.7.5 Danaher(Abcam) Recent Developments
  43. 4.8 Merck KGaA
  44. 4.8.1 Merck KGaA Company Information
  45. 4.8.2 Merck KGaA Business Overview
  46. 4.8.3 Merck KGaA Tumor Targeting Peptides Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Merck KGaA Tumor Targeting Peptides Product Portfolio
  48. 4.8.5 Merck KGaA Recent Developments
  49. 4.9 PEPTIDE INSTITUTE
  50. 4.9.1 PEPTIDE INSTITUTE Company Information
  51. 4.9.2 PEPTIDE INSTITUTE Business Overview
  52. 4.9.3 PEPTIDE INSTITUTE Tumor Targeting Peptides Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 PEPTIDE INSTITUTE Tumor Targeting Peptides Product Portfolio
  54. 4.9.5 PEPTIDE INSTITUTE Recent Developments
  55. 4.10 RayBiotech
  56. 4.10.1 RayBiotech Company Information
  57. 4.10.2 RayBiotech Business Overview
  58. 4.10.3 RayBiotech Tumor Targeting Peptides Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 RayBiotech Tumor Targeting Peptides Product Portfolio
  60. 4.10.5 RayBiotech Recent Developments
  61. 4.11 Selleck Chemicals
  62. 4.11.1 Selleck Chemicals Company Information
  63. 4.11.2 Selleck Chemicals Business Overview
  64. 4.11.3 Selleck Chemicals Tumor Targeting Peptides Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Selleck Chemicals Tumor Targeting Peptides Product Portfolio
  66. 4.11.5 Selleck Chemicals Recent Developments
  67. 4.12 TargetMol Chemicals
  68. 4.12.1 TargetMol Chemicals Company Information
  69. 4.12.2 TargetMol Chemicals Business Overview
  70. 4.12.3 TargetMol Chemicals Tumor Targeting Peptides Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 TargetMol Chemicals Tumor Targeting Peptides Product Portfolio
  72. 4.12.5 TargetMol Chemicals Recent Developments
  73. 4.13 Cayman Chemical
  74. 4.13.1 Cayman Chemical Company Information
  75. 4.13.2 Cayman Chemical Business Overview
  76. 4.13.3 Cayman Chemical Tumor Targeting Peptides Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Cayman Chemical Tumor Targeting Peptides Product Portfolio
  78. 4.13.5 Cayman Chemical Recent Developments
  79. 4.14 QYAOBIO
  80. 4.14.1 QYAOBIO Company Information
  81. 4.14.2 QYAOBIO Business Overview
  82. 4.14.3 QYAOBIO Tumor Targeting Peptides Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 QYAOBIO Tumor Targeting Peptides Product Portfolio
  84. 4.14.5 QYAOBIO Recent Developments
5 Global Tumor Targeting Peptides Market Scenario by Region
  1. 5.1 Global Tumor Targeting Peptides Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Tumor Targeting Peptides Sales by Region: 2021-2032
  3. 5.2.1 Global Tumor Targeting Peptides Sales by Region: 2021-2026
  4. 5.2.2 Global Tumor Targeting Peptides Sales by Region: 2027-2032
  5. 5.3 Global Tumor Targeting Peptides Revenue by Region: 2021-2032
  6. 5.3.1 Global Tumor Targeting Peptides Revenue by Region: 2021-2026
  7. 5.3.2 Global Tumor Targeting Peptides Revenue by Region: 2027-2032
  8. 5.4 North America Tumor Targeting Peptides Market Facts & Figures by Country
  9. 5.4.1 North America Tumor Targeting Peptides Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Tumor Targeting Peptides Sales by Country (2021-2032)
  11. 5.4.3 North America Tumor Targeting Peptides Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Tumor Targeting Peptides Market Facts & Figures by Country
  16. 5.5.1 Europe Tumor Targeting Peptides Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Tumor Targeting Peptides Sales by Country (2021-2032)
  18. 5.5.3 Europe Tumor Targeting Peptides Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Tumor Targeting Peptides Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Tumor Targeting Peptides Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Tumor Targeting Peptides Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Tumor Targeting Peptides Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Tumor Targeting Peptides Market Facts & Figures by Country
  41. 5.7.1 South America Tumor Targeting Peptides Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Tumor Targeting Peptides Sales by Country (2021-2032)
  43. 5.7.3 South America Tumor Targeting Peptides Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Tumor Targeting Peptides Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Tumor Targeting Peptides Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Tumor Targeting Peptides Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Tumor Targeting Peptides Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Tumor Targeting Peptides Sales by Type (2021-2032)
  2. 6.1.1 Global Tumor Targeting Peptides Sales by Type (2021-2032) & (Kg)
  3. 6.1.2 Global Tumor Targeting Peptides Sales Market Share by Type (2021-2032)
  4. 6.2 Global Tumor Targeting Peptides Revenue by Type (2021-2032)
  5. 6.2.1 Global Tumor Targeting Peptides Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Tumor Targeting Peptides Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Tumor Targeting Peptides Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Tumor Targeting Peptides Sales by Application (2021-2032)
  2. 7.1.1 Global Tumor Targeting Peptides Sales by Application (2021-2032) & (Kg)
  3. 7.1.2 Global Tumor Targeting Peptides Sales Market Share by Application (2021-2032)
  4. 7.2 Global Tumor Targeting Peptides Revenue by Application (2021-2032)
  5. 7.2.1 Global Tumor Targeting Peptides Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Tumor Targeting Peptides Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Tumor Targeting Peptides Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Tumor Targeting Peptides Value Chain Analysis
  2. 8.1.1 Tumor Targeting Peptides Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Tumor Targeting Peptides Production Mode & Process
  5. 8.2 Tumor Targeting Peptides Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Tumor Targeting Peptides Distributors
  8. 8.2.3 Tumor Targeting Peptides Customers
9 Global Tumor Targeting Peptides Analyzing Market Dynamics
  1. 9.1 Tumor Targeting Peptides Industry Trends
  2. 9.2 Tumor Targeting Peptides Industry Drivers
  3. 9.3 Tumor Targeting Peptides Industry Opportunities and Challenges
  4. 9.4 Tumor Targeting Peptides Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst